Arthneeti

Wockhardt Q4 FY26 Share Price & Earnings Call Analysis

₹1,922.90+0.50% today
Market cap
₹31,247 Cr
P/E
78.39
ROE
6.11%
PEG
1.80
Price to sales
8.76
Debt to equity
0.45
52W high / low
₹2,330 / ₹1,100
Sales growth (5Y)
4.49%
EBITDA margin
21.66%
Net profit margin
8.01%
Promoter holding
49.09%
Sales (last year)
₹3,564 Cr

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]

Guidance scorecard · Q4 FY26 call

What Wockhardt Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#15of 83 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ4 FY26 call

20–40%
  • Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months.
  • Significant market share goal of about 20-25% of resistant cases long-term.
  • Biosimilar business to double within 24 to 36 months driven by capacity expansion and pipeline product launches.
  • Capex of INR 200-300 crores planned over next three years, mainly in biologicals capacity.
  • Initial 12-18 months of slight loss or neutral profitability expected during market organization establishment for Zaynich, followed by strong profitability growth.
  • Overall company growth inherent due to multiple molecules without needing acquisitions.
  • India biosimilar market opportunity estimated at $6-7 billion.

2 more points from Wockhardt Ltd's call on revenue

Create a free account to keep reading this call

Full Q4 FY26 analysis

MarginsQ4 FY26 call

Flat

See what Wockhardt Ltd said on margins — free account, 30 seconds.

Full Q4 FY26 analysis

CapexQ4 FY26 call

Planned
  • Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity.
  • Investment in increasing biosimilar capacity, aiming to double capacity within 12 to 15 months.
  • Continued R&D spends at a consistent percentage of sales to support product pipeline development.
  • Focus on building a new business model and organizational capabilities for commercialization of innovative drugs like Zaynich, involving upfront revenue costs rather than capex.

2 more points from Wockhardt Ltd's call on capex

Create a free account to keep reading this call

Full Q4 FY26 analysis

FundraisingQ4 FY26 call

See what Wockhardt Ltd said on fundraising — free account, 30 seconds.

Full Q4 FY26 analysis

Order bookQ4 FY26 call

Ask what Wockhardt Ltd said on the order book →

Full Q4 FY26 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Wockhardt Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Wockhardt Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Wockhardt Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Wockhardt Ltd

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +678644753701700739809721743738782888965
Expenses +675628681664759648699593679666604711740
Operating Profit3167237-59911101286472178177225
OPM %0%2%10%5%-8%12%14%18%9%10%23%20%23%
Other Income +-64024810309815-77211567
Interest76797677737373604848556050
Depreciation56555555585455555356536553
Profit before tax-193-118-35-87-180-6-921-22-1099167189
Tax %23%15%109%-1%-2%167%78%5%105%-1%10%9%13%
Net Profit +-237-136-73-86-177-16-1620-45-1088261164
EPS in Rs-14.44-9.30-5.34-5.76-11.02-0.91-1.430.86-1.54-5.544.803.6310.22

Financials of Wockhardt Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +4,4824,4534,0153,9373,5662,8442,7083,2302,6512,7983,0123,373
Expenses +3,7723,9594,0023,9353,6042,7252,7712,9322,5502,7072,6192,721
Operating Profit709494132-38119-6329810191393652
OPM %16%11%0%0%-1%4%-2%9%4%3%13%19%
Other Income +6766114-238116133975-163-172176226
Interest55129225255265276249299302305254213
Depreciation145142149150164224246247251223217227
Profit before tax575289-247-641-351-247417-411-624-420-16238
Tax %28%13%-9%4%-38%-82%-65%-32%-0%12%256%16%
Net Profit +413252-226-667-217-43689-279-621-472-57199
EPS in Rs28.3017.45-13.62-42.30-13.52-4.8147.64-16.94-38.80-30.18-2.8913.11
Dividend Payout %54%0%-56%0%0%0%0%0%0%0%0%0%

Financials of Wockhardt Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital555555555555557272778181
Reserves3,3623,7203,2812,7972,6192,6163,3213,7773,2823,2824,2724,859
Borrowings +2,3092,6774,1603,7483,3753,5822,6732,1982,1842,3562,0212,233
Other Liabilities +1,2131,6221,4861,5281,7641,8941,6952,1682,1131,8991,7261,442
Total Liabilities6,9398,0748,9828,1287,8138,1487,7448,2157,6517,6148,1008,615
Fixed Assets +2,1232,8092,7732,8883,0583,5023,3433,4623,0422,8812,7364,499
CWIP1,0071,0361,2441,4331,4451,5851,3791,3421,5391,7222,033671
Investments3410563214000000422412
Other Assets +3,4684,2284,4033,5933,3093,0603,0223,4113,0703,0112,9093,033
Total Assets6,9398,0748,9828,1287,8138,1487,7448,2157,6517,6148,1008,615

Financials of Wockhardt Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +355-42-26968183649-287413153219-22390
Cash from Investing Activity +-222-105-68463593-1471,471-204-118-138-780-241
Cash from Financing Activity +-761931,254-769-776-680-1,171-71-315334409-54
Net Cash Flow5746301-66-500-17813138-280415-39395
Free Cash Flow-76-105-678-238127486-4522022369-37776
CFO/OP73%-8%-1,887%4,697%-583%560%270%171%162%274%-13%63%

Financials of Wockhardt Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60919489130159124104110818064
Inventory Days250249243174183209257222216201234286
Days Payable136144117122187272186265285240191182
Cash Conversion Cycle17519622014112697195604141123168
Working Capital Days145236-56-51-171-133-116-186-148-2389
ROCE %10%7%-1%-1%-1%-1%-3%1%-0%-1%4%8%

Guidance history

How Wockhardt Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q4 FY26 call →20–40%FlatPlanned——
Q4 FY25 call →20–40%FlatPlannedPlanned—
Q3 FY23 call →20–40%Up 2%+PlannedPlanned—

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

80out of 100

Momentum score · price trend

80 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+47.2%84%
Last 6 months+37.8%84%
Last 3 months+1.0%65%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Wockhardt Ltd: 0.4 × 84 + 0.4 × 84 + 0.2 × 65 = 80.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Wockhardt Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd